How many insider trades does FilingIQ track for IBRX?

FilingIQ tracks 122 Form 4 insider transactions for IBRX (ImmunityBio, Inc.), covering filings from Mar 9, 2021 onwards. 23 of those were filed in the last 90 days.

Are IBRX insiders net buyers or net sellers?

Across the full Form 4 history for IBRX, 9 transactions (7%) were open-market purchases and 15 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does IBRX insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is IBRX in?

ImmunityBio, Inc. (IBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.89B.

IBRX insider trading

Healthcare

ImmunityBio, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

122

Last 90 days

Buys / sells

7% / 12%

Market cap

$5.89B

About ImmunityBio, Inc.

ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.

Company website: immunitybio.com

IBRX insider activity at a glance

FilingIQ has scored 122 insider transactions for IBRX since Mar 9, 2021. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 9 open-market purchases and 15 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on IBRX insider trades is 55.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live IBRX trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for IBRX?: FilingIQ tracks 122 Form 4 insider transactions for IBRX (ImmunityBio, Inc.), covering filings from Mar 9, 2021 onwards. 23 of those were filed in the last 90 days.
Are IBRX insiders net buyers or net sellers?: Across the full Form 4 history for IBRX, 9 transactions (7%) were open-market purchases and 15 (12%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does IBRX insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is IBRX in?: ImmunityBio, Inc. (IBRX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.89B.

Methodology & sources

Every IBRX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.